| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Exeter Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Panacea Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Armstrong Pharmaceuticals, Inc. was founded in 1955 as a manufacturer of specialty aerosol products. Armstrong produced a wide array of topical, personal care, and pharmaceutical products. Since 1993, Armstrong has focused exclusively on pharmaceutical
Bell Pharmaceuticals is a Belle Plaine, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.